Pharmacologic Treatment of Posttraumatic Stress Disorder Among Privately Insured Americans
The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
Objective Although psychological trauma affects millions of Americans, few studies have examined treatment of posttraumatic stress disorder (PTSD) in real-world service environments. This study explored pharmacological treatment of PTSD among privately insured individuals. Methods Data were from the MarketScan database, which compiles claims from private health insurance plans nationwide. Descriptive statistics and multivariate logistic regression were used to identify predictors of any use of a psychotropic medication and use of three medication classes: antidepressants, anxiolytics or sedative-hypnotics, and antipsychotics. Results Of 860,090 adult mental health care users in 2005, only 10,636 (1.2%) had a diagnosis of PTSD. Sixty percent of PTSD patients received any psychotropic medication: 74.3% of those received antidepressants, 73.7% received anxiolytics or sedative-hypnotics, and 21.3% received antipsychotics. Greater likelihood of any medication use was associated with greater use of mental health services and with several comorbid psychiatric disorders. Having a comorbid diagnosis of an indicated disorder was the most robust predictor of use of each of the three medication classes: major depressive disorder and dysthymia were most strongly associated with antidepressant use, schizophrenia and bipolar disorder were associated with antipsychotic use, and anxiety disorders were associated with use of anxiolytics or sedative-hypnotics. Conclusions Psychotropic medicatio…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A prior US study has reported frequent off-label medication use in routine clinical practice given the limited approved options for PTSD [27].”
From Patient journey before and after a formal post-traumatic stress disorder diagnosis in adults in the United States-a retrospective claims study (2023) · cites this paper as [27]
In the citing paper
“Additional medications may also be used to treat PTSD-related symptoms that may not be routinely addressed but may have emerged during the course of PTSD [18,27], which can lead to polypharmacy.”
From Patient journey before and after a formal post-traumatic stress disorder diagnosis in adults in the United States-a retrospective claims study (2023) · cites this paper as [27]
In the citing paper
“While the only medications approved for PTSD in the US are SSRIs (i.e.sertraline and paroxetine) [25], other medications may also be used off label [23,27]”
From Patient journey before and after a formal post-traumatic stress disorder diagnosis in adults in the United States-a retrospective claims study (2023) · cites this paper as [27]
Citations
Cites
Journal of Clinical Psychiatry
(2018) · Journal of Clinical Psychiatry · doi:10.5505/kpd · Cited by 13,651
National Trends in the Outpatient Treatment of Depression
Olfson, M. (2002) · JAMA · doi:10.1001/jama.287.2.203 · Cited by 847
National Trends in the Outpatient Treatment of Children and Adolescents With Antipsychotic Drugs
Olfson, M., Blanco, C., Liu, L., Moreno, C., & Laje, G. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.6.679 · Cited by 591
Stein, M. B., Kline, N. A., & Matloff, J. L. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.10.1777 · Cited by 347
Zohar, J., Amital, D., Miodownik, C., Kotler, M., Bleich, A., Lane, R. M., & Austin, C. (2002) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200204000-00013 · Cited by 218
Clozapine Treatment in a Population of Adults With Mental Retardation
Antonacci, D. J., & de Groot, C. M. (2000) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v61n0106 · Cited by 213
Low-Dose Risperidone as Adjunctive Therapy for Irritable Aggression in Posttraumatic Stress Disorder
Monnelly, E. P., Ciraulo, D. A., Knapp, C., & Keane, T. (2003) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200304000-00012 · Cited by 163
Hamner, M. B., Faldowski, R. A., Ulmer, H. G., Frueh, B. C., Huber, M. G., & Arana, G. W. (2003) · International Clinical Psychopharmacology · doi:10.1097/00004850-200301000-00001 · Cited by 162
Lack of Efficacy for Fluoxetine in PTSD: A Placebo Controlled Trial in Combat Veterans
Hertzberg, M. A., Feldman, M. E., Beckham, J. C., Kudler, H. S., & Davidson, J. R. T. (2000) · Annals of Clinical Psychiatry · doi:10.1023/a:1009076231175 · Cited by 161
Olanzapine in the treatment of post-traumatic stress disorder: a pilot study
Butterfield, M. I., Becker, M. E., Connor, K. M., Sutherland, S., Churchill, L. E., & Davidson, J. R. T. (2001) · International Clinical Psychopharmacology · doi:10.1097/00004850-200107000-00003 · Cited by 160
Research works printed but not linked: 9
- 2005, c Visits and days in treatment are for
- Tjaden P, 1998, Thoennes N: Prevalence, Incidence and Consequences of Violence Against Women: Findings From the National Violence Against Women Survey
- Foa EB, 2000, Friedman M: Effective Treatments for PTSD: Practice Guideline From the International Society of Traumatic Stress Studies
- Van der Kolk BA, 1994, Journal of Clinical Psychiatry, 55, 517
- 10.3109/10401230009147096 · DOI · Paper page
- Braun P, 1990, Journal of Clinical Psychiatry, 51, 236
- Gelpin E, 1996, Journal of Clinical Psychiatry, 57, 390
- Stanton MW, 2004, Employer-sponsored health insurance: trends in cost and access. Research in Action [Agency for Healthcare Research and Quality], no
- Villarreal G, 2007, Psychopharmacology Bulletin, 40, 6
Cited by
Benzodiazepines for PTSD: A Systematic Review and Meta-Analysis
GUINA, J., ROSSETTER, S. R., DeRHODES, B. J., NAHHAS, R. W., & WELTON, R. S. (2015) · Journal of Psychiatric Practice · doi:10.1097/pra.0000000000000091 · Cited by 341
“In our literature review, we attempted to capture every available study about BZDs in PTSD to examine 3 questions: (1) What are the effects of BZDs on the development of PTSD in trauma patients? (2) What are the effects of BZDs on PTSD-associated outcomes in patients with PTSD? (3) What are the effects of BZDs on PTSD…”
MethodBenzodiazepines I: Upping the Care on Downers: The Evidence of Risks, Benefits and Alternatives
Guina, J., & Merrill, B. (2018) · Journal of Clinical Medicine · doi:10.3390/jcm7020017 · Cited by 253
“Unfortunately, some of these factors—particularly SUDs and borderline personality disorder—also correlate with increased BZD prescriptions [20,22,23,25,26].”
BackgroundResultInfluentialFeder, A., Costi, S., Rutter, S. B., Collins, A. B., Govindarajulu, U., Jha, M. K., Horn, S. R., Kautz, M., Corniquel, M., Collins, K. A., et al. (2021) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2020.20050596 · Cited by 246
“Approximately 60% of patients with PTSD respond to SSRIs, and only 20% 2 30% achieve complete remission following pharmacotherapy (7), resulting in poly ‐ pharmacy in clinical practice (8, 9).”
BackgroundFoa, E. B., Gillihan, S. J., & Bryant, R. A. (2013) · Psychological Science in the Public Interest · doi:10.1177/1529100612468841 · Cited by 222
Treating nightmares and insomnia in posttraumatic stress disorder: A review of current evidence
Nappi, C. M., Drummond, S. P. A., & Hall, J. M. H. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.02.029 · Cited by 138
“Sedative hypnotics Though benzodiazepines and sedative hypnotics are commonly used in patients with PTSD (Harpaz-Rotem et al., 2008; Mohamed and Rosenheck, 2008), few studies have examined the efficacy of benzodiazepines for treatment of sleep disturbance in PTSD.”
BackgroundAre There Effective Psychopharmacologic Treatments for PTSD?
Akiki, T. J., & Abdallah, C. G. (2018) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.18ac12473 · Cited by 60
Treatment of posttraumatic stress disorder: Focus on pharmacotherapy
Ehret, M. (2019) · Mental Health Clinician · doi:10.9740/mhc.2019.11.373 · Cited by 53
“All treatment guidelines currently recommend against the use of benzodiazepines in the treatment of PTSD because of the lack of evidence for effectiveness and the risks associated with their use; nevertheless, 30% to 74% of patients with PTSD still receive prescriptions for them.(18,64) Benzodiazepines have been used…”
BackgroundHawkins, E. J., Malte, C. A., Imel, Z. E., Saxon, A. J., & Kivlahan, D. R. (2012) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2012.01.003 · Cited by 49
Post-traumatic stress disorder as a comorbidity: impact on disease outcomes
Cavalcanti-Ribeiro, P., Andrade-Nascimento, M., Morais-de-Jesus, M., de Medeiros, G. M., Daltro-Oliveira, R., conceição, J. O., Rocha, M. F. V., Miranda‐Scippa, Â., Koenen, K. C., & Quarantini, L. C. (2012) · Expert Review of Neurotherapeutics · doi:10.1586/ern.12.77 · Cited by 50
Gender Differences in Prescribing Among Veterans Diagnosed with Posttraumatic Stress Disorder
Bernardy, N. C., Lund, B. C., Alexander, B., Jenkyn, A. B., Schnurr, P. P., & Friedman, M. J. (2013) · Journal of General Internal Medicine · doi:10.1007/s11606-012-2260-9 · Cited by 44
“Unfortunately, there are virtually no data concerning prescribing differences across genders in VA, despite the prominent role that pharmacotherapy plays in the management of PTSD. Approximately 60 % of privately insured patients with PTSD receive pharmacotherapy for the disorder,5 while close to 80 % of veterans rece…”
BackgroundDo Benzodiazepines Reduce the Effectiveness of Exposure Therapy for Posttraumatic Stress Disorder?
Rosen, C. S., Greenbaum, M. A., Schnurr, P. P., Holmes, T. H., Brennan, P. L., & Friedman, M. J. (2013) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.13m08592 · Cited by 44
Traumatic Stress Produces Distinct Activations of GABAergic and Glutamatergic Neurons in Amygdala
Fang, Q., Li, Z., Huang, G.-D., Zhang, H., Chen, Y., Zhang, L., Ding, Z., Shi, J., Lü, L., & Yang, J. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00387 · Cited by 47
Post-traumatic stress disorder: emerging concepts of pharmacotherapy
Baker, D. G., Nievergelt, C. M., & Risbrough, V. B. (2009) · Expert Opinion on Emerging Drugs · doi:10.1517/14728210902972494 · Cited by 40
“In actual practice, medications are commonly used in the treatment of PTSD [63,64].”
BackgroundPathways to suicidal behavior in posttraumatic stress disorder*
Panagioti, M., Gooding, P. A., Dunn, G., & Tarrier, N. (2011) · Journal of Traumatic Stress · doi:10.1002/jts.20627 · Cited by 37
Harpaz‐Rotem, I., Rosenheck, R. A., Mohamed, S., Pietrzak, R. H., & Hoff, R. A. (2016) · BJPsych Open · doi:10.1192/bjpo.bp.115.002451 · Cited by 25
“As reported in other studies, individuals with coexisting diagnoses of substance use disorders and schizophrenia 9,10 were less likely to be prescribed anxiolytics/sedatives/hypnotics, perhaps to avoid the risk of addiction in this vulnerable sub-population.”
Self-citationPsychotherapy use in a privately insured population of patients diagnosed with a mental disorder
Harpaz‐Rotem, I., Libby, D. J., & Rosenheck, R. A. (2012) · Social Psychiatry and Psychiatric Epidemiology · doi:10.1007/s00127-012-0486-9 · Cited by 20
“This may be a result of ongoing reports of mixed results in randomized clinical trials on the effectiveness of pharmacological agents in the treatment of PTSD, specifically SSRIs [17, 18, 20, 37, 41], and may also reflect that PTSD is the only psychiatric diagnosis whose definition includes an experiential etiology—ex…”
ResultSelf-citationGuina, J., Nahhas, R. W., Goldberg, A., & Farnsworth, S. (2016) · Journal of Clinical Medicine · doi:10.3390/jcm5080070 · Cited by 21
“Repetitive intimate partner violence, sexual assault, and physical abuse are all associated with increased PTSD-SUD comorbidity [16].”
BackgroundInfluentialGilbert, M., La, A. D., Delapaz, N. R., Hor, W. K., Fan, P., Qi, X., Guo, X., Ying, J., & Wang, L. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9113492 · Cited by 20
“Between 30% and 74% of PTSD patients have been prescribed a benzodiazepine in the past [18].”
BackgroundNovel Pharmacological Targets of Post-Traumatic Stress Disorders
Marazziti, D., Carmassi, C., Cappellato, G., Chiarantini, I., Massoni, L., Mucci, F., Arone, A., Violi, M., Palermo, S., Iorio, G. D., et al. (2023) · Life · doi:10.3390/life13081731 · Cited by 24
“Although the lack of significant differences between SSRIs and SNRIs has not been brought into question, the USA Food and Drug Administration (FDA) includes only paroxetine and sertraline [21,22].”
BackgroundDuek, O. A., Pietrzak, R. H., Petrakis, I. L., Hoff, R. A., & Harpaz‐Rotem, I. (2020) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2020.10.005 · Cited by 16
Self-citationValidating administrative records in post‐traumatic stress disorder
Abrams, T. E., Vaughan‐Sarrazin, M., Keane, T. M., & Richardson, K. K. (2015) · International Journal of Methods in Psychiatric Research · doi:10.1002/mpr.1470 · Cited by 16
“This is an important consideration because several papers have been written on patterns of pharmacotherapy for PTSD in the VHA with little validation of the ACD methods (Harpaz-Rotem et al., 2008; Lund et al., 2012; Mohamed and Rosenheck, 2008; Rosenheck and Fontana, 2007).”
BackgroundMethodInfluentialZhang, Z., Liu, R.-B., Zhang, J., Xian‐Yu, C., Liu, J.-L., Li, X., Zhang, Y., & Zhang, C. (2023) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2023.110754 · Cited by 17
“Benzodiazepine use to treat PTSD has not been studied in adequately powered randomized clinical trials, despite the fact that they are frequently used to treat anxiety and hyperarousal symptoms (Mohamed and Rosenheck, 2008; Harpaz-Rotem et al., 2008).”
Physical Injury, PTSD Symptoms, and Medication Use: Examination in Two Trauma Types
Cody, M. W., & Beck, J. G. (2014) · Journal of Traumatic Stress · doi:10.1002/jts.21880 · Cited by 18
“symptoms to predict use of not only psychiatric medications (Harpaz-Rotem et al., 2008) but also pain medications (Sansone et al.”
BackgroundFeder, A., Costi, S., Rutter, S., Collins, A. B., Govindarajulu, U. S., Jha, M. K., Horn, S. R. G.-V., Kautz, M. M., Corniquel, M. B., Collins, K. A., et al. (2023) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.23021014 · Cited by 17
Prolonged contextual fear memory in AMPA receptor palmitoylation-deficient mice
Oota-Ishigaki, A., Takao, K., Yamada, D., Sekiguchi, M., Itoh, M., Koshidata, Y., Abe, M., Natsume, R., Kaneko, M., Adachi, T., et al. (2022) · Neuropsychopharmacology · doi:10.1038/s41386-022-01347-9 · Cited by 12
Initial Presentation Sites as Predictors of Herpes Zoster Complications: A Nationwide Cohort Study
Wang, W.-Y., Liu, S.-H., Lin, M., Lin, C.-C., & Wang, I. (2016) · PLoS ONE · doi:10.1371/journal.pone.0164019 · Cited by 11
Updates on Pharmacological Treatment of Post-Traumatic Stress Disorder
Koirala, R., Søegaard, E. G. I., & Thapa, S. B. (2017) · Journal of Nepal Medical Association · doi:10.31729/jnma.3108 · Cited by 11
Pharmacological Treatment Following Traumatic Bereavement: A Case Series
Cacciatore, J., & Thieleman, K. (2012) · Journal of Loss and Trauma · doi:10.1080/15325024.2012.688699 · Cited by 8
“The authors expressed concern at the off-label (not approved by the FDA) usage of this class of medication and speculated that clinicians may be targeting specific symptoms with various medications (Harpaz-Rotem et al., 2008).”
BackgroundDavis, L. L., Urganus, A., Gagnon-Sanschagrin, P., Maitland, J., Qu, W., Cloutier, M., Guérin, A., & Aggarwal, J. (2023) · Current Medical Research and Opinion · doi:10.1080/03007995.2023.2269839 · Cited by 6
“A prior US study has reported frequent off-label medication use in routine clinical practice given the limited approved options for PTSD [27].”
BackgroundInfluentialPTSD biomarkers: Neuroendocrine signaling to epigenetic variants
Sbisa, A. M., Graham, K., Lawrence‐Wood, E., McFARLANE, A. C., & Toben, C. G. (2024) · Advances in clinical chemistry · doi:10.1016/bs.acc.2024.06.004 · Cited by 4
Suarez, E. B. (2012) · TSpace (University of Toronto) · Cited by 11
Mulvaney, S. W., Mahadevan, S., Dineen, K. J., Desronvilles, R. J., & Olmsted, K. R. (2025) · Clinical and Translational Neuroscience · doi:10.3390/ctn9010007 · Cited by 4
Marazziti, D., Crowther, L. F., & Arone, A. (2024) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2024.2355259 · Cited by 5
“%) of receiving a drug prescription for this disorder than men [55].”
BackgroundCook, J. M., Zeber, J. E., Simiola, V., Rossom, R. C., Scherrer, J. F., Owen‐Smith, A. A., Ahmedani, B. K., Zolfaghari, K., & Copeland, L. A. (2020) · Journal of Clinical Psychology in Medical Settings · doi:10.1007/s10880-020-09706-8 · Cited by 5
Haering, S., Meyer, C., Knaevelsrud, C., & Engel, S. (2025) · Der Nervenarzt · doi:10.1007/s00115-025-01907-6 · Cited by 4
Patient journey of civilian adults diagnosed with posttraumatic stress disorder—A chart review study
Davis, L. L., Urganus, A., Gagnon‐Sanschagrin, P., Maitland, J., Bedard, J., Bellefleur, R., Cloutier, M., Guérin, A., & Aggarwal, J. (2024) · Current Medical Research and Opinion · doi:10.1080/03007995.2024.2308016 · Cited by 3
“…treatments are also recommended 16 , and real-world studies have suggested that pharmacological treatments may be used to manage more severe PTSD symptoms and PTSD-related comorbidities in clinical practice 18,19 ; but with limited approved options, symptoms can be difficult to manage.”
BackgroundResultBenzodiazepine Therapy: The Good, the Bad, and the Ugly
Guina, J., Merrill, B., & LeQuang, J. A. (2020) · Oxford University Press eBooks · doi:10.1093/med/9780197517277.003.0003 · Cited by 2
Treatments for Post-traumatic Stress Disorder: Pharmaceutical and Electrophysiologic Considerations
Baker, D. G., Lerman, I., Espejo, E. P., & McLay, R. N. (2015) · Current Treatment Options in Psychiatry · doi:10.1007/s40501-015-0035-8 · Cited by 3
Montavon, F., Vandenberghe, F., & Eap, C. B. (2022) · L Encéphale · doi:10.1016/j.encep.2022.03.011 · Cited by 2
How and why does the pharmaceutical management of PTSD differ between men and women?
Bernardy, N. C., & Friedman, M. J. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2016.1199686 · Cited by 2
Psychotropic Medication Claims Among Religious Clergy
Frenk, S. M., Mustillo, S., Foy, S. L., Arroyave, W. D., Hooten, E. G., Lauderback, K. H., & Meador, K. G. (2012) · Psychiatric Quarterly · doi:10.1007/s11126-012-9224-4 · Cited by 2
“adult population, an increase in age is associated with a greater likelihood of having a claim for psychotropic medication [22–25, 39].”
BackgroundTomko, C. A., Schneider, K. E., Nestadt, D. F., Zemlak, J. L., & Sherman, S. G. (2023) · International Journal of Mental Health and Addiction · doi:10.1007/s11469-023-01169-w · Cited by 1
“…with a history of a substance use disorder due to abuse potential with chronic use, yet patients with PTSD and substance use disorders are more likely than their counterparts without substance use disorders to be prescribed benzodiazepines (Harpaz-Rotem et al., 2008; Mohamed & Rosenheck, 2008).”
Post-Traumatic Stress Disorder in Men
Terhaag, S., Pedder, D. J., Sbisa, A. M., & Forbes, D. (2021) · Cambridge University Press eBooks · doi:10.1017/9781108646765.011 · Cited by 2
Hicks, P. B. (2008) · Defense Technical Information Center (DTIC) · doi:10.21236/ada488880
Frenk, S. M., Mustillo, S., Foy, S. L., Arroyave, W. D., Hooten, E. G., Lauderback, K. H., & Meador, K. G. (2013)
Treatments for Post-traumatic Stress Disorder: Pharmaceutical and Electrophysiologic
Baker, C. G., Lerman, I., Espejo, E. P., & McLay, R. N. (2015)
Current awareness in human psychopharmacology
(2009) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.973
Leroy, A., Genon, M., Baubet, T., & Vaïva, G. (2022) · HAL · doi:10.1016/s0246-1072(22)87543-x · Cited by 1
PTSD, cannabis use, and expected symptom relief: gender-moderated mediational effects
Ueno, L. F. (2023) · Scholars Archive - University at Albany (University at Albany, State University of New York) · doi:10.54014/n5dz-yakb
Suzuki, N., Oota-Ishigaki, A., Iijima, K., Takayama, Y., Kimura, Y., Hattori, K., Iwasaki, M., & Hayashi, T. (2025) · Biochemical Pharmacology · doi:10.1016/j.bcp.2025.117426 · Cited by 1
Gonzalez‐Torres, C., Seens, H., & Sharma, V. (2026) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2026.2725862
“A study showed that 60% of participants with PTSD were treated pharmacologically, and both women and older participants were more likely to receive antidepressants and anxiolytics or sedative hypnotics [32].”
Metadata
- Authors
- Harpaz-Rotem, I., Rosenheck, R. A., Mohamed, S., & Desai, R. A.
- Venue
- Psychiatric Services
- Published
- 2008-10
- Volume
- 59
- Issue
- 10
- Pages
- 1184-1190
- ISSN
- 0022-1597 (ISSN-L)
- 1075-2730
- 1557-9700
- OpenAlex
- W4233357649
- Cited by
- 51
- References
- 25
- Citations by year
- 2026: 1 · 2025: 3 · 2024: 3 · 2023: 6 · 2022: 3 · 2021: 2 · 2020: 4 · 2019: 1 · 2018: 3 · 2017: 1 · 2016: 4 · 2015: 4 · 2014: 1 · 2013: 4 · 2012: 6
- FWCI
- 1.86
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Psychiatric Services (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Posttraumatic Stress Disorder Research
- Health Sciences › Medicine › Clinical Neurology › Traumatic Brain Injury Research
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Sleep and related disorders
- Keywords
- post-traumatic stress disorder, pharmacotherapy, antidepressants, private health insurance, treatment utilization
- MeSH terms
- Adult, Female, Humans, Insurance, Health, Male, Middle Aged, Stress Disorders, Post-Traumatic, United States, Comorbidity, Logistic Models, Private Sector, Insurance Coverage, Health Care Surveys, Databases as Topic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.